The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback